Blood
MorphoSys Trial for Blood-Cancer Treatment Reaches Primary Endpoint
20
Nov
Nov
By Ben Glickman
MorphoSys said its study of a treatment for myelofibrosis, a rare form of blood cancer, reached its primary endpoint, clearing the way for a new drug application in mid-2024.
The German pharmaceutical company said Monday its Phase 3 trial of pelabresib in combination with ruxolitinib in myelofibrosis patients found a statistically…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
